主讲嘉宾：黃嘉良(Ka-Leung Wong)教授香港浸会大学

讲座主持：方岩雄教授

讲座时间：2018年10月17日（周三）上午10:30-11:30

讲座地点：广东工业大学工学四号馆202会议室

嘉宾简介：

 The research of Prof. Ka-Leung Wong (Gary) mainly focuses on lanthanide chemistry for spectroscopic studies, molecular imaging and cancer therapy. He completed the PhD degree under the supervision of Professor Wing-Tak Wong at the University of Hong Kong in 2006 and was awarded a Royal Society post-doctoral fellowship with Professor David Parker at Durham University in 2008. He joined the Department of Chemistry at Hong Kong Baptist University as a faculty member and was promoted to Professor in 2017 and Head of Department in February 2018. Prof. Wong has published more than 100 articles in peer reviewed journals. He serves as the main editor of Journal of Luminescence (Elsevier) and is a member of the international advisory board of ChemPlusChem (Wiley). He was also awarded an international prize, the 2015 European Rare Earth and Actinide Society (ERES) Junior Award. He is a co-founder of the spinoff company ‘‘New Life Medicine Technology Company Limited’’.

报告摘要:One of the major limitations of the existing anticancer agents is their differentiation of cancer cells and normal cells. Recently, some studies in the literature have suggested that some overexpressed cancer cell cycle regulating proteins (e.g. Cyclin(s), Plk1 and EBNA1) can be the particular cancer targets. Several small molecules as their inhibitors have been reported; however, those reported inhibitors are not emissive and cannot directly evaluate their effectiveness, such as real time imaging, biodistribution and pharmacokinetic studies. In this seminar, I would like to share our development recently on emissive organic molecules ligated with peptides as dual bioprobes for in vitro/in vivo imaging and inhibition of overexpressed tumor regulator proteins, such as Cyclin(s), Plk1 and EBNA1. It is hoped that the success in research could also lead to the success in practice, thereby providing more powerful tools to get more complete pictures of the roles of Cyclin(s)/Plk1/EBNA1, especially EBNA1 for ending EBV associated cancers.

References:

1. S. Zha, K.-L. Wong,* et al. Nanoscale, (2018) 15632;

2. L. Jiang, K.-L. Wong,* et al. Theranoistic, (2018) In Press;

3. L. Jiang, K.-L. Wong,* et al. Nature Biomedical Engineering, (2017) 0042;

4. A. Nonat, K.-L. Wong*, L. J. Charbonnière * Nature Communications, et al. (2016) 11978;

5. L. Jiang, K.-L. Wong,* et al. Chemical Communications, 50 (2014) 6517.